ReviewWorld journal of psychiatry2025
Early diagnosis of bipolar disorder.
Review in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bipolar disorder (BD) is a severe mood disorder characterized by recurrent episodes of mania and depression, and it is prone to delayed diagnosis, which can lead to worsened outcomes, including more frequent mood episodes, greater functional impairment, and comorbidities. Early diagnosis of BD remains a significant challenge, although recent advances offer promising insights, such as research in molecular biomarkers, neuroimaging, exosomes, genetics, and epigenetics. This mini-review highlights their potential for providing earlier, more accurate identification of BD and discusses the underlying reasons why current research has not yet succeeded. For instance, the high heterogeneity of symptomatic presentations leads to low consistency in study participants; delayed BD diagnosis results in the inclusion of potential BD patients in the depression group; low specificity of biomarkers stems from limited understanding of BD pathophysiology; and there is a possibility that BD is not innate but develops over the course of the disease. Deepening our understanding of BD pathology, identifying more specific biomarkers, and integrating multiomics approaches for validation studies in well-defined homogeneous cohorts hold promise for significant breakthroughs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.